| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 |
| Sales | 168,900 | 113,860 | 173,340 | 132,770 | 153,340 |
| Sales Growth | +48.34% | -34.31% | +30.56% | -13.41% | +48.89% |
| Net Income | -108,550 | -5,250 | 32,040 | 109,680 | -66,970 |
| Net Income Growth | -1,967.62% | -116.39% | -70.79% | +263.77% | -487.97% |
Alvotech (ALVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Alvotech Holdings S.A. is a biotech company. It focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech Holdings S.A., formerly known as Oaktree Acquisition Corp. II, is based in REYKJAVIK, Iceland.
Fiscal Year End Date: 12/31